Back to Directory
Forcefield Therapeutics
Founded 2020
Preclinical cardioprotective proteins for heart attack treatment
Forcefield Therapeutics is a preclinical biotechnology company developing cardioprotective protein therapies for acute myocardial infarction.
Its programme uses naturally occurring proteins identified through the FunSel discovery platform to protect cardiomyocytes after a heart attack, reduce tissue damage and potentially limit progression to heart failure.
The company is backed by Syncona and Roche Venture Fund following a 2024 Series A financing. Its therapeutic approach remains investigational, with efficacy supported by preclinical rather than patient outcomes.
Company Notes
Member of